- Open Access
Persistence of pulmonary tertiary lymphoid tissues and anti-nuclear antibodies following cessation of cigarette smoke exposure
© Morissette et al.; licensee BioMed Central Ltd. 2014
- Received: 5 December 2013
- Accepted: 11 April 2014
- Published: 22 April 2014
Formation of pulmonary tertiary immune structures is a characteristic feature of advanced COPD. In the current study, we investigated the mechanisms of tertiary lymphoid tissue (TLT) formation in the lungs of cigarette smoke-exposed mice. We found that cigarette smoke exposure led to TLT formation that persisted following smoking cessation. TLTs consisted predominantly of IgM positive B cells, while plasma cells in close proximity to TLTs expressed IgM, IgG, and IgA. The presence of TLT formation was associated with anti-nuclear autoantibody (ANA) production that also persisted following smoking cessation. ANAs were observed in the lungs, but not the circulation of cigarette smoke-exposed mice. Similarly, we observed ANA in the sputum of COPD patients where levels correlated with disease severity and were refractory to steroid treatment. Both ANA production and TLT formation were dependent on interleukin-1 receptor 1 (IL-1R1) expression. Contrary to TLT and ANA, lung neutrophilia resolved following smoking cessation. These data suggest a differential regulation of innate and B cell-related immune inflammatory processes associated with cigarette smoke exposure. Moreover, our study further emphasizes the importance of interleukin-1 (IL-1) signaling pathways in cigarette smoke-related pulmonary pathogenesis.
- Tertiary lymphoid tissue
- Experimental model
Cigarette smoking is well know for its adverse health impacts, being a leading risk factor for most cancers, as well as cardiovascular and respiratory diseases . Currently, emphasis has been placed on reducing smoking prevalence; however, a greater understanding of the mechanisms of cigarette smoke’s adverse effects on human health is equally relevant given the addictive nature and chronic persistence of cigarette smoking, and the burden tobacco use places on healthcare .
It is widely accepted that inflammatory processes elicited by cigarette smoke play an important role in the pathogenesis of chronic obstructive pulmonary disease (COPD). Over the past decades, great advances have been made in our understanding of molecular pathways involved in driving cigarette smoke-induced inflammation [2, 3]. Emphasis has been placed on innate immune cells, including alveolar macrophages and neutrophils, for their destructive potential as reactive oxygen species and proteases released by these cells may cause tissue damage . More recently, there is emerging interest in the role of the adaptive immune system . It has been postulated that persistent inflammation associated with cigarette smoking may promote autoimmune processes , as evidenced by the occurrence of circulating autoantibodies in COPD patients [6–8]. Mechanisms driving these autoimmune processes remain poorly understood. Of particular interest is the formation of pulmonary tertiary lymphoid tissues as a potential inductive site of autoantibodies in patients with advanced COPD.
Cytokines play a key role in orchestrating cigarette smoke-induced inflammatory processes. To date, more than 50 cytokines and chemokines of interest have been reported . Of particular interest is interleukin-1 (IL-1) as it regulates innate and adaptive immune processes. Doz and colleagues demonstrated a critical role for interleukin-1 receptor 1 (IL-1R1), the receptor for both IL-1α and IL-1β, in cigarette smoke-induced neutrophilia . Parallel studies by Churg et al. showed that IL-1R1 KO mice were protected against cigarette smoke-induced emphysema formation . More recently, we reported that IL-1R1 signaling pathways were required for dendritic cell expansion and T cell activation following cigarette smoke exposure . The relative importance of IL-1R1 in tertiary lymphoid tissue (TLT) formation and autoantibody production is currently unknown.
The objective of this study was to investigate whether cigarette smoke exposure leads to the formation of pulmonary TLT and autoantibody production using a pre-clinical model of cigarette smoke exposure, as well as to determine the importance of IL-1R1 in these processes. We report the formation of TLT in mice exposed to cigarette smoke that persists following smoking cessation. We further show the presence of broad-spectrum autoantibodies recognizing anti-nuclear antigens in the lungs that persist following smoking cessation. ANA were also observed in the sputum of COPD patients. Studies in gene deficient mice showed that TLT and ANA formation were IL-1R1-dependent. Our study shows that chronic cigarette smoke exposure induces adaptive immune processes that persist following smoking cessation. These findings further emphasize the importance of IL-1 signaling pathways in cigarette smoke-related pulmonary pathologies as well as B cell and innate immune responses.
Female BALB/c mice (6-8 weeks old) were purchased from Charles River Laboratories (Montreal, PQ, Canada). Female, 6-8 weeks old C57BL/6 and IL-1R1-/- (C57BL/6 background) mice were purchased from The Jackson Laboratories (Bar Harbor, ME). All mice were kept in a 12-h light-dark cycle with food and water ad libidum. The McMaster University Animal Research Ethics Board approved all experiments described in this study.
Cigarette smoke exposure
Mice were exposed to cigarette smoke for 4 days, 8 weeks and 24 weeks using a whole-body exposure system (SIU48, PROMECH LAB AB, Vintrie, Sweden) as previously described in detail [13, 14]. Briefly, mice were exposed to the mainstream smoke of twelve 3R4F reference cigarettes (University of Kentucky, Lexington, USA) with filters removed. Mice were exposed 5 days per week, twice daily, for 50 minutes/exposure. Total particulate matter in the exposure chamber was measured weekly and ranged from 600 to 700 μg/L. We previously reported that cigarette smoke exposure is well tolerated and results in cotinine and carboxyhemoglobin levels comparable to human smokers . Control animals were exposed to room air only.
Collection of mouse specimens
Bronchoalveolar lavage (BAL), lung tissue, and blood were collected as previously described [13, 14]. Total cell counts in the BAL were determined using a haemocytometer. BAL cytospins were prepared for differential cell counts and stained with Hema 3 as per the manufacturer’s instructions (Biochemical Sciences Inc., Swedesboro, New Jersey, USA). At least 300 leukocytes were counted per cytospin. BAL fluid was stored at -80°C. Blood was collected by retro-orbital bleeding, serum was obtained and stored at -80°C. For histological assessment, the left lung was inflated with 10% neutral buffered formalin at a constant pressure of 30 cm of water, and then fixed in 10% neutral buffered formalin for 72 hours.
All clinical samples were collected with patients’ informed written consent and ethical approval from the Research Ethic Board at McMaster University. Sputum induction was performed as described by Pizzichini et al.. Spirometry was performed according to standards of the American Thoracic Society.
CXCL13 and anti-nuclear antibodies measurement
Bronchoalveolar lavage levels of CXCL13 were measured by ELISA according to manufacturer’s specifications (R&D systems, Minneapolis, MN). Anti-nuclear antibodies were measured by ELISA. Nuclei were isolated from TC-1 cells (mouse lung epithelial cell line; grown according to ATCC guidelines) and A549 cells (human adenocarcinoma cell line; grown according to ATCC guidelines) according to manufacturer’s specifications (Nuclear extraction kit, Millipore, CA). NUNC 96-well plates (Nalge Nunc international, NY) were dry-coated with 1 μg of nuclear protein per well in 100 μl of water overnight at 37°C. Wells were washed three times (0.05% TWEEN-20 in PBS) prior to incubation with either mouse BALF (1:2 dilution), mouse serum (1:500 dilution) or human sputum supernatant (1:10 dilution) at room temperature (RT) for two hours. Plates were washed 3 times (0.05% TWEEN-20 in PBS) prior to incubation with the detection antibody for 1 hour at RT. Total mouse ANA were detected using rabbit anti-mouse conjugated to horseradish peroxidase (HRP) (1:1000; Invitrogen, NY). For isotype specific detection, wells were incubated with biotinylated goat anti-mouse IgM, IgA, or IgG (1/1000; Sigma Aldrich), washed, and incubated with streptavidin-HRP. Total human ANA were detected using anti-human immunoglobulin conjugated to HRP (1:1000; Invitrogen, NY). Wells were washed then incubated with chromogen TMB substrate (BioFX Laboratories, MD) and optical density was measured at 450 nm. The assay was validated using the serum and BALF of the autoimmune New Zealand Black (NZB) mouse as a positive control (Additional file 1: Figure S1).
Formalin-fixed, paraffin-embedded lungs were cut into 4 μm thick cross-sections and stained with hematoxylin and eosin. Four photos at a 16x magnification were taken for every lung. Whole lung cross-section area (Lungarea [pixel2/1010]) as well as the number of bronchus-associated TLT (TLTnumber) were determined using the Image J Software and identified according to their distinctive morphology. Data are expressed as bronchus-associated TLTs per lung area (TLTnumber/Lungarea).
Three micrometer thick sections from formalin-fixed, paraffin-embedded lungs were stained by immunochemistry for B220, CD138, IgM, IgA and IgG protein expression. Briefly, lung sections were deparaffinized in xylene and rehydrated in ethanol:water. Endogenous peroxidases were blocked in 3% H2O2 in methanol. Citrate buffer antigen retrieval was performed (45 minutes). Sections were blocked with 1% swine serum in TBS 0.01% Tween 20. Sections were stained at 4°C overnight with either rat anti-mouse B220 (1:50; Abcam), rabbit anti-mouse CD138, biotinylated goat anti-mouse IgM, IgA or IgG. Antibodies were detected with a biotinylated goat anti-rat IgG (B220) or anti-rabbit IgG (CD138) (1:100; 1 h RT; BioLegend) followed by streptavidin-HRP (DACO) or directly by streptavidin-HRP (IgM, IgA, IgG). Staining was visualized using 3-amino-9-ethylcarbazole (AEC) substrate reagent. Sections were counterstained with hematoxylin. Negative staining controls are presented in Additional file 1: Figure S2.
Statistical analyses were performed using StatView Software. Two-group comparisons were made using an unpaired Student’s t-test with a significant threshold at 0.05. Experimental protocols with more than two groups were compared using a two-way ANOVA (significant threshold at 0.05) followed, if applicable, by a Bonnferoni post-hoc test.
Chronic cigarette smoke exposure leads to persistent tertiary lymphoid tissue formation in the lung
Characterization of B cells within pulmonary tertiary lymphoid tissue and localization of immunoglobulin-secreting cells
Cigarette smoke exposure elicits local but not systemic production of anti-nuclear autoantibodies
ANA levels are elevated in COPD patients and are refractory to steroid treatment
Gold 0/1 (n = 7)
Gold 2 (n = 23)
Gold 3/4 (n = 17)
FEV 1 , % pred.
85.4 (5.8) *
59.2 (9.2) ‡
36.2 (8.2) #
FEV 1 /FVC, %
73.0 (11.3) *
55.0 (9.9) ‡
38.3 (8.9) #
Gold 2/3/4 no steroid use (n = 10)
Gold 2/3/4 Steroid use (n = 19)
66.8 (6.5) *
59.3 (8.4) ‡
FEV 1 , % pred.
57.0 (12.0) *
45.4 (13.3) ‡
FEV 1 /FVC, %
54.9 (12.8) *
44.1 (9.1) ‡
Neutrophilic inflammation Resolves following chronic cigarette smoke exposure
Role of IL-1 signaling in cigarette smoke-induced neutrophilia, elevated pulmonary anti-nuclear antibodies and TLT formation
Clinical evidence suggests that cigarette smoking leads to TLT formation in the lung; however, the mechanisms that lead to the formation of these tertiary lymphoid tissues and their association with autoimmune processes are at present unknown. The objective of the current study was to investigate the mechanisms of TLT formation and autoantibody production using a mouse model of cigarette smoke exposure.
To investigate cigarette smoke’s impact on TLT formation, we utilized a well-characterized murine model of cigarette smoke exposure [13, 14, 20]. We previously reported that cigarette smoke exposure is well tolerated and leads to cotinine and carboxyhemoglobin levels comparable to human smokers thus validating the experimental approach . In the current study, we report that exposure to cigarette smoke led to pulmonary TLT formation that persisted following smoking cessation. B cells within TLTs preferentially expressed membrane-bound IgM, while plasma cells expressing IgM, IgG, or IgA were located in areas adjacent to TLTs. These findings suggest that TLTs are a site of B cell activation, leading to plasma cell differentiation and antibody production within the lungs.
A key observation of this study is that formation of lung tertiary lymphoid tissues was strongly associated with persistently increased levels of ANA following smoking cessation. We analyzed anti-nuclear antibodies (ANA) since they are a broad-spectrum class of autoantibodies that are associated with a number of autoimmune disorders in both humans and experimental models [21, 22]. The increase in ANA levels was observed in the lungs, but not in the circulation of cigarette smoke-exposed mice. While we observed a transient increase in ANA IgG following 8 weeks of cigarette smoke exposure, ANA IgA was the predominant isotype after 24 weeks. This shift towards IgA provides further evidence of local autoantibody production, as IgA is the isotype associated with mucosal tissues. This may signify that these autoimmune processes are confined to the lungs and lack the systemic component that is observed in other autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, or Sjögren’s syndrome [21, 23, 24].
While lung TLT are a characteristic feature of advanced COPD , the function of this lymphoid structures remain poorly understood. Studies by Bracke and colleagues  suggest that TLTs do not contribute to emphysema formation in cigarette smoke-exposed mice. While autoantibodies were present in cigarette smoke exposed mice prior to TLT formation, sustained presence of ANA after smoking cessation was only observed in the presence of pulmonary TLTs. It is plausible that these structures might be a site of continuous activation of B cells even following smoking cessation and the generation of autoantibody-producing plasma cells.
In line with our observations in cigarette smoke-exposed mice, we show a significant increase in ANA levels in the sputum of GOLD stage 2/3/4 COPD patients compared to GOLD stage 0/1 subjects thus providing evidence that sputum autoantibodies levels correlate with disease severity. Of note, ANA levels in the sputum were steroid insensitive; similar levels were observed in patients that received steroid treatment compared to patients that were not treated with steroids. While there is increasing evidence that autoantibodies are detected in the circulation of COPD patients [9–11], several reports did not confirm these observations [19, 20]. Our findings suggest that autoantibodies associated with COPD may be more reliably detected in sputum and provide evidence that cigarette smoke elicits autoimmune processes specifically within the lungs.
Mechanistically, we demonstrated that cigarette smoke-induced TLT formation and ANA production is IL-1R1-dependent. These findings further highlight the importance of IL-1R1 signaling pathways in cigarette smoke-induced inflammation. We, and others, have previously shown that cigarette smoke-induced neutrophilia [10, 25, 26] and formation of emphysematous damage is, at least in part, IL-1R1 dependent . Of note, IL-1R1 signaling pathways were required for the induction of CXCL-13, a chemokine that plays a critical role in TLT formation following cigarette smoke exposure , suggesting that the absence of TLT in the lung of IL-1R1-/- mice may be caused by a lack of CXCL13 upregulation. Of particular interest to our current study is that dendritic cell expansion and T cell activation following cigarette smoke exposure are also IL-1R1 dependent . Hence, the ability of cigarette smoke to induce autoimmune processes may be subsequent to dendritic cell activation as postulated by Cosio and colleagues .
To the best of our knowledge, we are the first to document that IL-1R1 plays a critical role in cigarette smoke-induced ANA and TLT formation. While little is known about the role of IL-1R1 in autoimmunity, Croker et al. reported that autoimmune processes observed in Ptp6n-/- mice (deficient in SHP1 protein) were IL-1R1 dependent . Interestingly, autoimmunity in this model was likely triggered by the host’s microflora, as germ-free Ptp6n-/- mice did not exhibit the phenotype. While mechanisms leading to inflammation and autoimmunity remain to be elucidated in the Ptp6n-/- mice, the underlying processes are similar to the IL-1R1 dependency of cigarette smoke-induced ANA production and BALT formation.
Cigarette smoke exposure is a leading risk factor for many diseases such as cancer, cardiovascular diseases, and COPD which reflects the complexity of its effects on the human body. Data presented here demonstrate that cigarette smoke induces local ANA production that is associated with the presence of pulmonary TLTs. Our data further highlights the importance of IL-1 signaling pathways in innate and adaptive immune inflammatory processes associated with COPD pathology.
The work described herein was funded in part by the CIHR and MedImmune LLC; MCM holds a Canadian Thoracic Society Fellowship, a FRSQ Fellowship and a Flight Attendant Medical Research Institute (FAMRI; http://www.famri.org) Young Clinical Scientist Award; JKN and PS hold Ontario Graduate Studentships.
The work described herein was funded in part by the Canadian Institutes of Health Research (MOP-64390) and MedImmune LLC.
- U.S. Department of Health and Human Services: How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. 2010, Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and HealthGoogle Scholar
- Barnes PJ, Shapiro SD, Pauwels RA: Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003, 22: 672-688. 10.1183/09031936.03.00040703.PubMedView ArticleGoogle Scholar
- Stampfli MR, Anderson GP: How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol. 2009, 9: 377-384. 10.1038/nri2530.PubMedView ArticleGoogle Scholar
- Dale DC, Boxer L, Liles WC: The phagocytes: neutrophils and monocytes. Blood. 2008, 112: 935-945. 10.1182/blood-2007-12-077917.PubMedView ArticleGoogle Scholar
- Cosio MG, Saetta M, Agusti A: Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009, 360: 2445-2454. 10.1056/NEJMra0804752.PubMedView ArticleGoogle Scholar
- Karayama M, Inui N, Suda T, Nakamura Y, Nakamura H, Chida K: Anti-endothelial cell antibodies in patients with COPD. Chest. 2010 Dec, 138 (6): 1303-1308. 10.1378/chest.10-0863.PubMedView ArticleGoogle Scholar
- Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S, Green L, Hacken-Bitar J, Huh J, Bakaeen F, Coxson HO, Cogswell S, Storness-Bliss C, Corry DB, Kheradmand F: Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med. 2007, 13: 567-569. 10.1038/nm1583.PubMedView ArticleGoogle Scholar
- Núñez B, Sauleda J, Antó JM, Julià MR, Orozco M, Monsó E, Noguera A, Gómez FP, Garcia-Aymerich J, Agustí A: Anti-tissue antibodies are related to lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011, 183: 1025-1031. 10.1164/rccm.201001-0029OC.PubMedView ArticleGoogle Scholar
- Barnes PJ: Mediators of chronic obstructive pulmonary disease. Pharmacol Rev. 2004, 56: 515-548. 10.1124/pr.56.4.2.PubMedView ArticleGoogle Scholar
- Doz E, Noulin N, Boichot E, Guénon I, Fick L, Le Bert M, Lagente V, Ryffel B, Schnyder B, Quesniaux VF, Couillin I: Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J Immunol. 2008, 180: 1169-1178. 10.4049/jimmunol.180.2.1169.PubMedView ArticleGoogle Scholar
- Churg A, Zhou S, Wang X, Wang R, Wright JL: The role of interleukin-1beta in murine cigarette smoke-induced emphysema and small airway remodeling. Am J Respir Cell Mol Biol. 2009, 40: 482-490. 10.1165/rcmb.2008-0038OC.PubMedView ArticleGoogle Scholar
- Botelho FM, Nikota JK, Bauer CM, Morissette MC, Iwakura Y, Kolbeck R, Finch D, Humbles AA, Stämpfli MR: Cigarette smoke-induced accumulation of lung dendritic cells is interleukin-1alpha-dependent in mice. Respir Res. 2012, 13: 81-10.1186/1465-9921-13-81.PubMedPubMed CentralView ArticleGoogle Scholar
- Botelho FM, Gaschler GJ, Kianpour S, Zavitz CC, Trimble NJ, Nikota JK, Bauer CM, Stämpfli MR: Innate immune processes are sufficient for driving cigarette smoke-induced inflammation in mice. Am J Respir Cell Mol Biol. 2010, 42: 394-403. 10.1165/rcmb.2008-0301OC.PubMedView ArticleGoogle Scholar
- Gaschler GJ, Zavitz CC, Bauer CM, Stampfli MR: Mechanisms of clearance of nontypeable Haemophilus influenzae from cigarette smoke-exposed mouse lungs. Eur Respir J. 2010 Nov, 36 (5): 1131-1142. 10.1183/09031936.00113909.PubMedView ArticleGoogle Scholar
- Pizzichini E, Pizzichini MM, Efthimiadis A, Hargreave FE, Dolovich J: Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination. Eur Respir J. 1996, 9: 1174-1180. 10.1183/09031936.96.09061174.PubMedView ArticleGoogle Scholar
- Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Paré PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004, 350: 2645-2653. 10.1056/NEJMoa032158.PubMedView ArticleGoogle Scholar
- Bonarius HP, Brandsma CA, Kerstjens HA, Koerts JA, Kerkhof M, Nizankowska-Mogilnicka E, Roozendaal C, Postma DS, Timens W: Antinuclear autoantibodies are more prevalent in COPD in association with low body mass index but not with smoking history. Thorax. 2011, 66: 101-107. 10.1136/thx.2009.134171.PubMedView ArticleGoogle Scholar
- Feghali-Bostwick CA, Gadgil AS, Otterbein LE, Pilewski JM, Stoner MW, Csizmadia E, Zhang Y, Sciurba FC, Duncan SR: Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008, 177: 156-163. 10.1164/rccm.200701-014OC.PubMedPubMed CentralView ArticleGoogle Scholar
- Bracke KR, Verhamme FM, Seys LJ, Bantsimba-Malanda C, Cunoosamy DM, Herbst R, Hammad H, Lambrecht BN, Joos GF, Brusselle GG: Role of CXCL13 in cigarette smoke-induced lymphoid follicle formation and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013, 188: 343-355. 10.1164/rccm.201211-2055OC.PubMedView ArticleGoogle Scholar
- Bauer CM, Zavitz CC, Botelho FM, Lambert KN, Brown EG, Mossman KL, Taylor JD, Stämpfli MR: Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS One. 2010, 5: e13251-10.1371/journal.pone.0013251.PubMedPubMed CentralView ArticleGoogle Scholar
- Scofield RH: Autoantibodies as predictors of disease. Lancet. 2004, 363: 1544-1546. 10.1016/S0140-6736(04)16154-0.PubMedView ArticleGoogle Scholar
- Mohan C: Murine lupus genetics: lessons learned. Curr Opin Rheumatol. 2001, 13: 352-360. 10.1097/00002281-200109000-00003.PubMedView ArticleGoogle Scholar
- Jonsson R, Vogelsang P, Volchenkov R, Espinosa A, Wahren-Herlenius M, Appel S: The complexity of Sjogren's syndrome: novel aspects on pathogenesis. Immunol Lett. 2011, 141: 1-9. 10.1016/j.imlet.2011.06.007.PubMedView ArticleGoogle Scholar
- Conrad K, Roggenbuck D, Reinhold D, Dorner T: Profiling of rheumatoid arthritis associated autoantibodies. Autoimmun Rev. 2010, 9: 431-435. 10.1016/j.autrev.2009.11.017.PubMedView ArticleGoogle Scholar
- Botelho FM, Bauer CM, Finch D, Nikota JK, Zavitz CC, Kelly A, Lambert KN, Piper S, Foster ML, Goldring JJ, Wedzicha JA, Bassett J, Bramson J, Iwakura Y, Sleeman M, Kolbeck R, Coyle AJ, Humbles AA, Stämpfli MR: IL-1alpha/IL-1R1 expression in chronic obstructive pulmonary disease and mechanistic relevance to smoke-induced neutrophilia in mice. PLoS One. 2011, 6: e28457-10.1371/journal.pone.0028457.PubMedPubMed CentralView ArticleGoogle Scholar
- Pauwels NS, Bracke KR, Dupont LL, Van Pottelberge GR, Provoost S, Vanden Berghe T, Vandenabeele P, Lambrecht BN, Joos GF, Brusselle GG: Role of IL-1alpha and the Nlrp3/caspase-1/IL-1beta axis in cigarette smoke-induced pulmonary inflammation and COPD. Eur Respir J. 2011, 38: 1019-1028. 10.1183/09031936.00158110.PubMedView ArticleGoogle Scholar
- Croker BA, Lawson BR, Rutschmann S, Berger M, Eidenschenk C, Blasius AL, Moresco EM, Sovath S, Cengia L, Shultz LD, Theofilopoulos AN, Pettersson S, Beutler BA: Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger. Proc Natl Acad Sci U S A. 2008, 105: 15028-15033. 10.1073/pnas.0806619105.PubMedPubMed CentralView ArticleGoogle Scholar
- Rutgers SR, Postma DS, ten Hacken NH, Kauffman HF, van Der Mark TW, Koëter GH, Timens W: Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax. 2000, 55: 12-18. 10.1136/thorax.55.1.12.PubMedPubMed CentralView ArticleGoogle Scholar
- Lapperre TS, Postma DS, Gosman MM, Snoeck-Stroband JB, ten Hacken NH, Hiemstra PS, Timens W, Sterk PJ, Mauad T: Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax. 2006, 61: 115-121. 10.1136/thx.2005.040519.PubMedPubMed CentralView ArticleGoogle Scholar
- Tang H, Yan C, Cao J, Sarma JV, Haura EB, Wu M, Gao H: An essential role for Stat3 in regulating IgG immune complex-induced pulmonary inflammation. FASEB J. 2011, 25: 4292-4300. 10.1096/fj.11-187955.PubMedPubMed CentralView ArticleGoogle Scholar
- Fudala R, Krupa A, Matthay MA, Allen TC, Kurdowska AK: Anti-IL-8 autoantibody:IL-8 immune complexes suppress spontaneous apoptosis of neutrophils. Am J Physiol Lung Cell Mol Physiol. 2007, 293: L364-L374. 10.1152/ajplung.00179.2006.PubMedView ArticleGoogle Scholar
- Marsh CB, Pomerantz RP, Parker JM, Winnard AV, Mazzaferri EL, Moldovan N, Kelley TW, Beck E, Wewers MD: Regulation of monocyte survival in vitro by deposited IgG: role of macrophage colony-stimulating factor. J Immunol. 1999, 162: 6217-6225.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.